Alan Ezekowitz Biography and Net Worth

Director of Fulcrum Therapeutics

Alan Ezekowitz, MBChB, D.Phil, is currently a venture partner at Third Rock Ventures, LLC. Alan currently serves on the Board of Directors of Organon & Co. and Septerna, Inc. Alan Ezekowitz was president and CEO of Abide Therapeutics, a company he co-founded in 2011 until its acquisition by H. Lundbeck A/S in May 2019. Formerly, he was the senior vice president and franchise head for disease areas including bone, respiratory, immunology, muscle, urology and dermatology at Merck Research Laboratories. Prior to Merck, Alan was the Charles Wilder Professor of Pediatrics at Harvard Medical School and served as the chief of pediatric services at the Massachusetts General Hospital for Children and the Partners Healthcare System. Additionally, he directed the Laboratory of Developmental Immunology at Massachusetts General Hospital. Alan is a member of the American Society of Clinical Investigation and a fellow of the American Association for the Advancement of Science and has served on multiple National Institutes of Health subcommittees. He was honored by the establishment of the R. Alan Ezekowitz Professorship in Pediatrics at Harvard Medical School.

What is Alan Ezekowitz's net worth?: The estimated net worth of Alan Ezekowitz is at least $38.74 thousand as of June 26th, 2026. Dr. Ezekowitz owns 10,927 shares of Fulcrum Therapeutics stock worth more than $38,736 as of July 15th. This net worth approximation does not reflect any other assets that Dr. Ezekowitz may own. Learn More about Alan Ezekowitz's net worth.
How do I contact Alan Ezekowitz?: The corporate mailing address for Dr. Ezekowitz and other Fulcrum Therapeutics executives is 26 LANDSDOWNE STREET, CAMBRIDGE MA, 02139. Fulcrum Therapeutics can also be reached via phone at (617) 651-8851 and via email at [email protected]. Learn More on Alan Ezekowitz's contact information.
Has Alan Ezekowitz been buying or selling shares of Fulcrum Therapeutics?: Alan Ezekowitz has not been actively trading shares of Fulcrum Therapeutics during the past quarter. Most recently, Alan Ezekowitz sold 18,000 shares of the business's stock in a transaction on Friday, June 26th. The shares were sold at an average price of $3.65, for a transaction totalling $65,700.00. Following the completion of the sale, the director now directly owns 10,927 shares of the company's stock, valued at $39,883.55. Learn More on Alan Ezekowitz's trading history.
Who are Fulcrum Therapeutics' active insiders?: Fulcrum Therapeutics' insider roster includes Alan Ezekowitz (Director), James Geraghty (Director), Robert Gould (Insider), Christopher Morabito (Insider), Curtis Oltmans (SVP), and Peter Thomson (CEO). Learn More on Fulcrum Therapeutics' active insiders.
Are insiders buying or selling shares of Fulcrum Therapeutics?: During the last year, insiders at the sold shares 4 times. They sold a total of 4,223,139 shares worth more than $58,777,643.22. The most recent insider tranaction occured on June, 26th when Director Alan Ezekowitz sold 18,000 shares worth more than $65,700.00. Insiders at Fulcrum Therapeutics own 7.3% of the company. Learn More about insider trades at Fulcrum Therapeutics.
Information on this page was last updated on 6/26/2026.

Alan Ezekowitz Insider Trading History at Fulcrum Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
6/26/2026	Sell	18,000	$3.65	$65,700.00	10,927

Alan Ezekowitz Buying and Selling Activity at Fulcrum Therapeutics

Fulcrum Therapeutics Company Overview

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and MyoKardia, Inc. to discover and develop therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $3.51

$3.53

$3.62

50 Day Range

MA: $4.79

$3.14

$7.25

2 Week Range

Now: $3.51

$2.83

$15.74

Volume

500,606 shs

Average Volume

1,649,302 shs

Market Capitalization

$233.54 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

3.01